Arena Pharmaceuticals joins hand with Ortho-McNeil for diabetes drug

Arena Pharmaceuticals, Inc. announced to have partnership with Ortho-McNeil-Janssen Pharmaceuticals, Inc for first-in-human Phase 1 clinical trial of APD597, an oral drug to treat type 2 diabetes. Ortho-McNeil’s Phase 1 program will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597 in single and multiple ascending dose studies in healthy volunteers. Ortho-McNeil’s planned clinical studies will also include the evaluation of patients with type 2 diabetes.

The diabetes drug targets the glucose-dependent insulinotropic receptor (GDIR) for the treatment of type 2 diabetes. The GDIR was also discovered by Arena and has the potential to stimulate insulin release in response to increases in blood glucose.

About the Glucose-Dependent Insulinotropic Receptor (GDIR):
The GDIR is an orphan G protein-coupled receptor (GPCR), discovered by Arena. It is expressed in beta cells, the cells in the pancreas responsible for producing insulin in response to increases in blood glucose. The GDIR signals through a similar intracellular pathway as the GLP-1 receptor, with common downstream effects, but unlike the GLP-1 receptor, the GDIR has proven amenable to small molecule drug discovery.

Source: Marketwatch

Filed under Diabetes, Diabetes Drug, NIDDM | Tags: , , , | Comment Below


Leave a Reply

Protected by Comment Guard Pro